title: Risperidone in the management of violent, treatment-resistant schizophrenics hospitalized in a maximum security forensic facility.
abstract: This study examines the effectiveness of risperidone compared with traditional neuroleptic medications in the areas of clinical functioning and aggressive behaviors in a sample of inpatients diagnosed with chronic schizophrenia. Similar to the methodology of Menditto et al. (Psychiatr Serv 47:46-51, 1996), two groups of 10 patients were selected from those being treated in a comprehensive psychosocial rehabilitation program. Group 1 subjects were placed on risperidone at various times during their treatment. Group 2 subjects, who were matched with Group 1 subjects on pre-study levels of clinical functioning as measured by the Time-Sample Behavioral Checklist (TSBC), remained on traditional neuroleptics throughout the study period. For each subject, scores on six TSBC subscales were examined at four time points; data were analyzed with repeated-measures multivariate analyses of variance and univariate analyses of variance. Frequency counts of aggressive behaviors (threats and assaults) were compiled into two six-month time periods and analyzed with nonparametric techniques. The risperidone group did not differ from the traditional neuroleptic group on measures of clinical functioning and aggressiveness measured over time. Both groups evidenced improvements in bizarre motor behaviors over the study period. The risperidone group evidenced some deterioration in measures of appropriate interpersonal interaction over time. No differences in aggressive behaviors were noted for either group. The study concludes that for forensic patients with chronic schizophrenia, risperidone failed to produce therapeutic effects in overall clinical functioning and aggressive behaviors that were significantly different from traditional neuroleptics. Descriptive comparisons are made between the receptor-binding profiles and clinical effectiveness of risperidone and clozapine in an attempt to explain these findings.
authors.affiliation: Department of Psychiatry and Neurology, University of Missouri School of Medicine, Columbia 65201, USA.
authors.forename: N C
authors.initials: NC
authors.lastname: Beck
authors.forename: S R
authors.initials: SR
authors.lastname: Greenfield
authors.forename: H
authors.initials: H
authors.lastname: Gotham
authors.forename: A A
authors.initials: AA
authors.lastname: Menditto
authors.forename: P
authors.initials: P
authors.lastname: Stuve
authors.forename: C A
authors.initials: CA
authors.lastname: Hemme
mesh_terms: D000328:Adult; D000374:Aggression / Q000187:drug effects; D000704:Analysis of Variance; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D016009:Chi-Square Distribution; D005555:Forensic Psychiatry / Q000379:methods; D006760:Hospitalization; D006801:Humans; D008297:Male; D012189:Retrospective Studies; D018967:Risperidone / Q000627:therapeutic use*; D012559:Schizophrenia / Q000150:complications / Q000188:drug therapy* / Q000534:rehabilitation; D014754:Violence / Q000517:prevention & control*
chemical_list: D014150:Antipsychotic Agents; D018967:Risperidone